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Background
It is well known that many bioactive peptides (intra-
genic) are encrypted in source proteins and that they
can exert their function once released by proteolytic
cleavage; e.g. hypotensive, opioids and antimicrobial
peptides. However, other bioactive peptides may be
“stuck” on a polipeptide chain with no cleavage sites for
its release. These “non-obvious” intragenic peptides are
also of interest in the search for new biologically active
peptides, mainly antimicrobial peptides, in an alternative
way for new drug discovery and for the control of differ-
ent phytopathogens, mainly fungi, that can cause several
losses to different crops of interest; e.g. rice, soybean,
common bean, cocoa. In Brazil, Theobroma cacao pro-
duction can be decimate by the basidiomycete Moni-
liophtora perniciosa, the causative agent of cocoa witch’s
broom disease. In this report we present preliminary
results of the search, synthesis and activity of intragenic
antimicrobial peptides (IAPs) selected from Theobroma
cacao genome.
Methods
In this study, we performed a search of putative IAPs using
Theobroma cacao Matina 1.6 genome [1]. Search was per-
formed using the software Kamal v1.0 alpha [2] with user-
created parameters. Eleven peptides out of 700000 filtered
peptides were selected for in-house solid-phase synthesis.
DS01 [3] and Ascaphin-8 [4] were also synthesized as posi-
tive controls. Peptides were purified by RP-HPLC in a pre-
parative C18 column. The purity and molecular mass of
peptides were evaluated by MALDI-TOF MS (UltraFlex
III, Bruker Daltonics). Peptide fragmentation was obtained
by MALDI-TOF MS/MS experiments and the resulting
data were analyzed manually using Flex Analysis 3.0
(Bruker Daltonics) software to confirm synthetic peptides
aminoacid sequence. The minimum inhibitory concentra-
tions (MIC) of the synthetic peptides for Candida albicans
ATCC 90028 and Cryptococcus neoformans ATCC 28957
was determined by microdilution broth method, according
to CLSI M27-3a document [5] and were evaluated at con-
centrations between 256 μM-0.5 μM.
Results and conclusions
Pep2, Pep5, Pep6, Pep8 and Pep10 showed MICs against
C. neoformans ATCC and C. albicans ATCC. The data
obtained for DS01 and Ascaphin-8 for C. albicans showed
MICs of 6 and 8 μM, respectively, in agreement with the
literature [3,4]. Pep5 and Pep10 showed MICs of 128 and
64 μM, respectively. Pep6 and Pep8 inhibit C. albicans
and C. neoformans growth at 4 μM and 8 μM. Pep2 was
able to inhibit and kill both fungi at 2 μM. Pep2, 6 and
8 showed lower MIC values than DS01 and Ascaphin-8
for C. neoformans. Synthetic peptides 2, 6 and 8 showed
promising results against human pathogenic fungi high-
lighting the importance of this approach to search for new
drugs. To evaluate if this approach can render promising
results for agriculture, which is the main goal of our study,
MICs assays are being performed with some fungi phyto-
pathogens. This approach can be use as an alternative to
the transgenic technology as the plant own information,
not an exogenous one, could be used for the control of
phytopathogens, as proposed for soybean [2].
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